Group items tagged

t's true. Each year, more than 4.6 million men and 3.5 million women die of cancer globally, according to the 2014 World Cancer Report - compiled by the World Health Organization's International Agency for Research on Cancer (IARC) and published by Cancer Research U.K. That puts the global rate of cancer deaths among men - 126 for every 100,000 people - 50 percent higher than that of women, which is 82 deaths out of 100,000 people.

It sounds strange but standing on your alternative legs in the morning forces your body to maintain a good and healthy balance, thereby, strengthening your back muscles

It's true, not all frozen yogurt is fat free and some can be high in sugar content, however there are several healthy frozen yogurts available, such as Yogurt Bar's organic frozen yogurts that are non-fat and low calorie.

A large-scale European trial has indicated that frozen embryo transfers fail to deliver any improvement over fresh transfers during the in vitro fertilisation (IVF) process.

Medcloud is a patient-centered platform for diagnosis, focused on simplifying test management in all its phases. Unlike other medical imaging solutions..

A Orthodontic treatment should be carried out by qualified professionals round this time five years ago there was a surge in the reporting of people performing DIY orthodontics on themselves in their own homes. Mainstream media reported that video tutorials had emerged online with instructions on using small elastic bands to adjust teeth positions. What followed were some horrendous pictures of irreparable damage to people's teeth and gums. The trend escalated to a point where in 2017, the American Dental Association revealed that 13 per cent of patients had tried some kind of DIY teeth straightening appliance that had backfired. Now, we are seeing the situation further evolve, with private companies offering DIY orthodontic treatment under the term 'direct-to-consumer' orthodontics. The Oral Health Foundation is becoming increasingly concerned with the rise of the DIY orthodontic market and the potential harmful consequences it could have for millions of consumers.

The government has launched a consultation into radically changing the Statutory Scheme for branded medicines (known as the Statutory Scheme). The consultation comes as delicate negotiations for replacing the alternative Voluntary Scheme are underway, potentially undermining these talks, while also further damaging industry confidence in the UK as a viable place to research, launch and supply medicine. The government proposals seek to hold average revenue clawback rates under the Statutory Scheme at historic highs of between 21-27%, compared to the pre-pandemic averages of 9.4% for the Statutory Scheme (2019-2021), and 6.88% for the Voluntary Scheme (2014-2021). The accompanying cost-benefit analysis ignores any negative impact this may have on medicine supply and wrongly claims it will boost investment. The consultation comes on the heels of government data last week showing UK life sciences foreign direct investment (FDI) fell by 47% between 2021 and 2022, down by £900m year on year. This large fall in investment coincided with a rise in the main UK clawback rate under the Voluntary Scheme from 5% to 15%, and led to the UK falling from 2nd to 9th out of 18 comparator countries for life sciences FDI in 2022. The Voluntary Scheme clawback rate now sits at a record 26.5% in 2023.

The British Generic Manufacturers Association (BGMA) has sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines with the Association of the British Pharmaceutical Industry (ABPI). Mark Samuels, Chief Executive of BGMA said: "The Government has decided not to involve the trade body representing these medicine suppliers in its negotiations on the voluntary scheme for branded medicine pricing (VPAS). "We are deeply concerned by this decision. It has left us no choice but to take legal action." "While not all generic drugs fall within VPAS, four out of ten products in the current scheme are branded generics or biosimilars. As the representative trade body for both generic and biosimilar UK manufacturers, we must play a full part in the VPAS negotiations for the next period of the scheme from 2024 to 2028." "The VPAS tax has risen five-fold in under two years, an unprecedented tax increase. Yet our sector currently has no input into the negotiations on future schemes or rates; this is untenable as any decisions made on VPAS could significantly define the future of our sector in the UK and its ability to supply the NHS. The association had raised its full participation in the negotiations with the Government last November.

Japanese pharmaceutical firm Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for people with early symptoms, potentially getting the treatment to patients next year. It remains unclear how widely the drug developed with U.S. biotech Biogen Inc will be used due to uncertainty over insurance coverage, including the U.S. government's Medicare plan for people age 65 and over, potential side effects and cost. One Wall Street analyst told Reuters news agency that he is not counting on measurable sales until 2024. Several estimated lecanemab may be priced at around $20,000 per year. "Most people who this (drug) would apply to are on Medicare, and most private payers look to Medicare as they make their own (coverage) decisions. So there's a massive roadblock in the way of all who could benefit from this treatment," said Robert Egge, Alzheimer's Association chief public policy officer. Eisai confirmed on Tuesday (November 30) that lecanemab - an antibody designed to remove sticky deposits of a protein called amyloid beta from the brain - reduced the rate of cognitive decline on a clinical dementia scale by 27% compared to a placebo. It also gave new details on side effects including a dangerous type of brain swelling and brain bleeding.

Pfizer and its German partner, BioNTech, fired back at Moderna on Monday in a patent lawsuit over their rival Covid-19 vaccines, seeking dismissal of the lawsuit in Boston federal court and an order that Moderna's patents are invalid and not infringed. Moderna first sued Pfizer in August, accusing the company of violating its rights in three patents related to innovations that Cambridge, Massachusetts-based Moderna said it pioneered before the Covid-19 pandemic. Moderna has also filed a related lawsuit against Pfizer and BioNTech in Germany. All three companies are also embroiled in US patent disputes with other companies over the vaccines. A Pfizer spokesperson said the company and BioNTech are confident in their intellectual property and will "vigorously defend" against Moderna's claims. Moderna did not immediately respond to a request for comment on the Monday filing.

The Association of the British Pharmaceutical Industry (ABPI) on Thursday (February 2) called for the government to scrap its plans to raise the repayment rates for drugmakers, to avoid possible setbacks in the sector. Drugmakers that are part of the government's voluntary scheme agreement, which makes branded medicines affordable for people, are required to pay a part of their drug revenue to the government. The Department of Health and Social Care plans to raise the revenue clawback rate to 27.5 per cent from 24.5 per cent. The country's ongoing attempt to raise rates is likely to send the "worst possible signal" to global investors and boardrooms, said the ABPI. "Hiking these clawbacks to such uncompetitive levels risks undermining the UK's offer to global life sciences companies," Richard Torbett, chief executive of the ABPI, said in a statement. Pharmaceuticals giants AbbVie and Eli Lilly withdrew from the UK's voluntary drug pricing agreement in January after the repayment rates surged to 26.5 per cent.

Insuman Comb 50 100units/ml suspension for injection 3ml cartridges has been discontinued with stocks being exhausted imminently, notified Department of Health and Social Care (DHSC). The department has issued a medicine supply notification for Insulin isophane biphasic human 50/50 (Insuman Comb 50) 100units/ml suspension for injection 3ml cartridge. "Humolog Mix 50 remains available, as do other biphasic insulin preparations, and the manufacturers can support a full uplift in supply," said DHSC. A copy of this medicine supply notification, including further information, has been sent to all pharmacy NHS email addresses. DHSC and NHSE/I's newly launched online Medicines Supply Tool provides up to date information about medicine supply issues. The contents of these MSNs can now be viewed on the Tool.

When it comes time to choose a Medicare plan, it can be difficult to know where to start. There are so many factors to consider, from the cost of coverage to the quality of care you'll receive. How do you know which plan is right for you? This article will discuss some of the most important things to keep in mind when choosing a Medicare plan. It will cover everything from drug coverage to hospital and doctor networks. By the end of this article, you'll be able to confidently choose the right Medicare plan for your needs! COST Of course, for most of us, the cost of our healthcare is a major consideration. When you're choosing a Medicare plan, you'll want to make sure that you're getting good value for your money. Be sure to compare the monthly premiums, deductibles, and copayments of each plan you're considering. You may also want to look at the total annual out-of-pocket costs for each plan. This will give you a good idea of how much your healthcare will actually cost you on a yearly basis. If you plan to be using Medicare for insurance, it's important to do your research before enrolling. This way, you can be sure that you're getting the best possible coverage for your needs and budget.

Department of Health and Social Care (DHSC) has issued a medicine supply notification for Oxcarbazepine (Trileptal) 300mg and 600mg tablets on Wednesday (14 June). It has notified that the Oxcarbazepine (Trileptal) 300mg tablets will be out of stock from late June 2023 until mid-July 2023 and Oxcarbazepine (Trileptal) 600mg tablets are out of stock until mid-July 2023. However, generic oxcarbazepine 300mg and 600mg tablets remain available and will be able to support increased demand. "Oxcarbazepine (Trileptal) 150mg tablets and generic oxcarbazepine 150mg tablets remain available but cannot support the increase in demand," said DHSC. "Oxcarbazepine (Trileptal) 60mg/ml oral suspension remains available but cannot meet an increase in demand."

Dentistry is one of the most important yet underappreciated professions in the world. Without dental professionals, our teeth would fall out, we wouldn't be able to eat correctly, and our overall health would suffer. That's why ensuring you're doing everything possible to succeed in dentistry is crucial. And one of the best ways to do that is to listen to the advice of those who have come before you. If you are looking for some great tips on how to make it in the world of dentistry, then you have come to the right place. Here are four pieces of advice that will help you succeed. ATTEND A REPUTABLE DENTISTRY SCHOOL To be a great dentist, you must start with an excellent education. And that means attending a reputable dentistry school. There are many different schools, so it's essential to do your research and find one that is right for you, and this article gives an example of a dentistry course program overview. Consider things like accreditation, curriculum, clinical experience, and more when deciding. Additionally, it's important to note that you don't necessarily need to attend the most expensive school to get an excellent education. There are many affordable schools out there that can provide you with everything you need to succeed.

A £5m project has been launched to introduce new blood tests in the National Health Service (NHS) that can diagnose Alzheimer's disease. The blood tests could be available on the NHS within five years and they can diagnose the disease earlier and more accurately than current methods, experts have said. Alzheimer's Research UK, the Alzheimer's Society and the National Institute of Health and Care Research have jointly launched the project. Susan Kohlhaas, Executive Director of Research and Partnerships at Alzheimer's Research UK, said that the NHS doesn't possess the "required levels of diagnostic infrastructure" to cope with the "growing demand" for dementia diagnosis. "Low-cost tools like blood tests that are non-invasive and simpler to administer than current gold standard methods are the answer to this," she added.

The Department of Health and Social Care (DHSC) has published the full text of the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG). The 2024 VPAG agreement text sets out the detailed terms of the agreement reached between DHSC, NHS England and the Association of the British Pharmaceutical Industry (ABPI) to support patient access to medicines, the financial sustainability of the NHS and the UK life sciences sector. The new voluntary scheme will come into force on 1 January 2024, following expiry of the 2019 Voluntary Scheme and shall remain in force for a period of five years, until 31 December 2028. Manufacturers or suppliers of branded medicines to the NHS have been given time till 15 January 2024 to decide whether to join the new 2024 Voluntary Scheme, or default to the updated Statutory Scheme.

NICE has recommended use of tucatinib as an option to treat HER2-positive breast cancer that has spread in people who have already tried 2 or more anti-HER2 treatments. The move is set to benefit around 400 people with advanced breast cancer. Tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading. The medicine is taken as two 150 mg tablets twice daily along with anti-cancer medicines trastuzumab and capecitabine. Helen Knight, programme director in the NICE Centre for Health Technology Evaluation, said: "Unfortunately there is no cure for breast cancer that has spread to other parts of the body. There is also a lack of additional anti‑HER2 treatments which can postpone the need for chemotherapy, especially for people whose cancer has spread to their brain because their treatment options are even more limited.

A smattering of monkeypox cases in Britain has prompted authorities to offer a smallpox vaccine to some healthcare workers and others who may have been exposed, as a handful more cases were confirmed in parts of Europe. Monkeypox is a usually mild viral illness, characterised by symptoms of fever as well as a distinctive bumpy rash. There are two main strains: the Congo strain, which is more severe - with up to 10 per cent mortality - and the West African strain, which has a fatality rate of about one per cent First identified in monkeys, the viral disease typically spreads through close contact and largely occurs in west and central Africa. It has rarely spread elsewhere, so this fresh spate of cases outside the continent has triggered concern. In the United Kingdom, nine cases of the West African strain have been reported so far. There isn't a specific vaccine for monkeypox, but a smallpox vaccine does offer some protection, a UK Health Security Agency (UKHSA) spokesperson said. Data shows that vaccines that were used to eradicate smallpox are up to 85 per cent effective against monkeypox, according to the World Health Organisation.